Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.

Plain English (For Everyone)

A court has decided that Moderna's COVID-19 vaccines do not violate Alnylam Pharmaceuticals' patents for the technology used to deliver the vaccine's active ingredients. This means the vaccine can continue to be used without infringing on Alnylam's intellectual property rights. The decision upholds a lower court's ruling and resolves a major patent dispute.

For Legal Practitioners

The Federal Circuit affirmed summary judgment of non-infringement, holding that Moderna's accused mRNA vaccines do not practice every element of Alnylam's asserted LNP delivery system patent claims. The court's de novo review focused on claim construction, finding that Moderna's products did not meet specific limitations regarding LNP composition and use, thus avoiding literal infringement.

For Law Students

This case illustrates the application of the doctrine of literal patent infringement. The Federal Circuit reviewed de novo whether Moderna's mRNA vaccines infringed Alnylam's LNP delivery patents. The court found no infringement because Moderna's products did not meet all limitations of Alnylam's asserted claims, emphasizing the importance of precise claim language and element-by-element analysis.

Newsroom Summary

A federal appeals court has ruled that Moderna's COVID-19 vaccines do not infringe on patents held by Alnylam Pharmaceuticals related to the delivery system. The decision upholds a lower court's finding and resolves a significant intellectual property dispute in the biotechnology sector.

Standard of Review

The Court of Appeals for the Federal Circuit reviews a district court's grant of summary judgment of non-infringement de novo. This means the appellate court looks at the issue fresh, without giving deference to the lower court's decision, to determine if the law was applied correctly.

Procedural Posture

This case reached the Federal Circuit on appeal from the United States District Court for the District of Massachusetts, which had granted summary judgment of non-infringement in favor of Moderna. Alnylam Pharmaceuticals appealed this decision.

Burden of Proof

The burden of proof for patent infringement lies with the patent holder, Alnylam Pharmaceuticals. To prove infringement, Alnylam had to show that Moderna's accused products practiced every element of at least one of Alnylam's asserted patent claims. The standard is whether the evidence presented demonstrates infringement by a preponderance of the evidence.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

The district court correctly determined that Moderna's accused products do not infringe the asserted claims of Alnylam's patents.

To prove literal infringement, Alnylam must show that Moderna's accused products practice every element of at least one of Alnylam's asserted claims.

Remedies

Affirmed the district court's grant of summary judgment of non-infringement.

Parties

• United States Court of Appeals for the Federal Circuit (party)

Scenario: You are a pharmaceutical company developing a new drug using a patented delivery system. You believe your product is different enough not to infringe.

Your Rights: You have the right to develop and market your product if it does not meet every element of a competitor's patent claim. However, you must carefully analyze the patent claims and your product's features to avoid infringement.

What To Do: Conduct a thorough freedom-to-operate analysis, including claim construction and comparison of your product's features against each element of relevant patents. Consult with patent counsel to assess infringement risk and potential invalidity arguments.

Is it legal to use a technology that is similar to a patented one?

Depends. It is legal to use a technology similar to a patented one as long as your product or process does not meet every single element of at least one of the patent's claims. If your product is identical or covers every limitation of a claim, it likely constitutes infringement.

This applies to U.S. patent law.

For Biotechnology and Pharmaceutical Companies

This ruling reinforces the importance of precise patent claim drafting and the need for thorough infringement analysis. Companies must ensure their products do not literally infringe on existing patents by meeting all claim limitations, while also providing clarity for innovators regarding the scope of their intellectual property.

For Patent Holders

Patent holders need to ensure their claims are clearly written and encompass the innovations they seek to protect. This decision highlights that even with similar technology, failure to meet specific claim limitations can result in a finding of non-infringement.

Q: What is Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. about?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. is a case decided by Federal Circuit on June 4, 2025.

Q: What court decided Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. decided?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. was decided on June 4, 2025.

Q: What is the citation for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

The citation for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. is 138 F.4th 1326. Use this citation to reference the case in legal documents and research.

Q: What type of patents were at issue in Alnylam v. Moderna?

The patents at issue related to Alnylam's lipid nanoparticle (LNP) delivery systems, which are crucial for delivering mRNA in vaccines. The dispute centered on whether Moderna's LNP technology infringed these patents.

Q: What is a lipid nanoparticle (LNP) delivery system?

An LNP is a tiny particle made of fats (lipids) used to carry and deliver therapeutic molecules, such as mRNA, into cells. It's a key technology for mRNA vaccines.

Q: What is the 'Federal Circuit'?

The United States Court of Appeals for the Federal Circuit is a specialized appellate court that has exclusive jurisdiction over appeals in patent cases from U.S. district courts.

Q: Is Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. published?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What topics does Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. cover?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. covers the following legal topics: Patent infringement, Claim construction, Doctrine of equivalents, Lipid nanoparticle (LNP) delivery systems, mRNA vaccines, Biotechnology patents.

Q: What was the ruling in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

The court ruled in favor of the defendant in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.. Key holdings: The court held that Moderna's accused mRNA vaccines did not infringe Alnylam's asserted patent claims because the accused products did not contain the specific lipid components recited in the claims.; The court affirmed the district court's construction of the patent claims, finding it was not clearly erroneous and correctly interpreted the scope of the asserted limitations.; The court rejected Alnylam's argument that the doctrine of equivalents should apply, finding that the differences between the accused products and the claimed invention were substantial and not insubstantial.; The court affirmed the jury's verdict of non-infringement, finding substantial evidence supported the jury's factual findings regarding the composition of Moderna's vaccines.; The court affirmed the district court's exclusion of certain expert testimony offered by Alnylam, finding it was not relevant or reliable under the Daubert standard..

Q: Why is Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. important?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. has an impact score of 65/100, indicating significant legal impact. This decision highlights the critical role of specific claim language in patent infringement cases, especially in the fast-paced biotechnology sector. It underscores that even for groundbreaking technologies like mRNA vaccines, patent protection is tied to the precise scope of the claims, and the doctrine of equivalents has limitations when accused products deviate substantially from the patented invention.

Q: What precedent does Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. set?

Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. established the following key holdings: (1) The court held that Moderna's accused mRNA vaccines did not infringe Alnylam's asserted patent claims because the accused products did not contain the specific lipid components recited in the claims. (2) The court affirmed the district court's construction of the patent claims, finding it was not clearly erroneous and correctly interpreted the scope of the asserted limitations. (3) The court rejected Alnylam's argument that the doctrine of equivalents should apply, finding that the differences between the accused products and the claimed invention were substantial and not insubstantial. (4) The court affirmed the jury's verdict of non-infringement, finding substantial evidence supported the jury's factual findings regarding the composition of Moderna's vaccines. (5) The court affirmed the district court's exclusion of certain expert testimony offered by Alnylam, finding it was not relevant or reliable under the Daubert standard.

Q: What are the key holdings in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

1. The court held that Moderna's accused mRNA vaccines did not infringe Alnylam's asserted patent claims because the accused products did not contain the specific lipid components recited in the claims. 2. The court affirmed the district court's construction of the patent claims, finding it was not clearly erroneous and correctly interpreted the scope of the asserted limitations. 3. The court rejected Alnylam's argument that the doctrine of equivalents should apply, finding that the differences between the accused products and the claimed invention were substantial and not insubstantial. 4. The court affirmed the jury's verdict of non-infringement, finding substantial evidence supported the jury's factual findings regarding the composition of Moderna's vaccines. 5. The court affirmed the district court's exclusion of certain expert testimony offered by Alnylam, finding it was not relevant or reliable under the Daubert standard.

Q: What cases are related to Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

Precedent cases cited or related to Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.: Warner-Jenkinson Co. v. Hilton Davis, Ltd., 520 U.S. 17 (1997); Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005); Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993).

Q: Did Moderna's COVID-19 vaccines infringe Alnylam's patents?

No, the Federal Circuit affirmed the district court's finding that Moderna's accused products do not infringe Alnylam's asserted patent claims. The court found that Moderna's vaccines did not practice every element of Alnylam's claims related to lipid nanoparticle delivery systems.

Q: What does it mean for a product to 'practice every element' of a patent claim?

To literally infringe a patent claim, an accused product must include every single limitation or element recited in that claim. If even one element is missing or not met, there is no literal infringement.

Q: Who had the burden of proof in this patent infringement case?

The burden of proof was on Alnylam Pharmaceuticals, the patent holder, to demonstrate that Moderna's vaccines infringed its patents. Alnylam had to show by a preponderance of the evidence that Moderna's products met all the limitations of at least one of Alnylam's asserted claims.

Q: Did the court consider the doctrine of equivalents?

The provided summary focuses on literal infringement. While the doctrine of equivalents is a separate path to infringement, the court's decision here was based on the finding that Moderna's products did not meet the specific elements of Alnylam's asserted claims.

Q: What is the significance of claim construction in patent cases like this?

Claim construction is fundamental because it defines the scope of the patent rights. The court's interpretation of Alnylam's patent claims regarding LNP characteristics was central to determining whether Moderna's products met those limitations.

Q: Could Alnylam have sued Moderna for infringement under the doctrine of equivalents?

The provided information focuses on literal infringement. While the doctrine of equivalents exists, the court's decision here was based on the lack of literal infringement, meaning Moderna's products did not meet all elements of the asserted claims.

Q: Does this ruling mean Alnylam has no valid patents related to LNP technology?

No, this ruling specifically addresses the asserted claims in this particular lawsuit and whether Moderna's accused products infringed them. It does not invalidate Alnylam's patents entirely or preclude them from asserting other claims or patents in different contexts.

Q: What is the difference between literal infringement and infringement under the doctrine of equivalents?

Literal infringement occurs when an accused product contains every element of a patent claim. Infringement under the doctrine of equivalents occurs when a product is not identical but performs substantially the same function in substantially the same way to achieve substantially the same result as the claimed invention.

Q: Are there any exceptions to patent infringement?

Yes, potential defenses include patent invalidity (e.g., the patent shouldn't have been granted), non-infringement (as found here), or specific exemptions like the 'experimental use' exception or the BPCIA safe harbor for biosimilars, though these are narrowly construed.

Q: How does Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. affect me?

This decision highlights the critical role of specific claim language in patent infringement cases, especially in the fast-paced biotechnology sector. It underscores that even for groundbreaking technologies like mRNA vaccines, patent protection is tied to the precise scope of the claims, and the doctrine of equivalents has limitations when accused products deviate substantially from the patented invention. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: How does this ruling affect the use of Moderna's COVID-19 vaccines?

The ruling means that Moderna's vaccines can continue to be used and marketed without infringing on the specific patents asserted by Alnylam in this case. It resolves a significant legal challenge to the vaccine's intellectual property.

Q: What are the practical implications for other companies developing mRNA technology?

Companies developing similar technologies must carefully analyze existing patents, particularly the specific language of patent claims, to ensure they do not infringe. This case highlights the importance of precise claim drafting and thorough freedom-to-operate analyses.

Q: What happens if a company is found to infringe a patent?

If found liable for patent infringement, a company may be ordered to pay damages (lost profits or reasonable royalties), be subject to an injunction preventing further sales or use of the infringing product, and potentially pay enhanced damages for willful infringement.

Q: How long do patent disputes typically take?

Patent disputes can be lengthy and complex, often involving multiple stages including discovery, claim construction, trial, and appeals. This case, like many patent disputes, involved significant time and resources.

Q: What was the docket number in Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.?

The docket number for Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. is 23-2357. This identifier is used to track the case through the court system.

Q: Can Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What is the standard of review for patent non-infringement decisions on appeal?

The Federal Circuit reviews a district court's grant of summary judgment of non-infringement de novo. This means the appellate court reviews the decision without giving deference to the lower court's findings.

Q: What was the outcome of the appeal?

The Federal Circuit affirmed the district court's decision, upholding the finding of non-infringement. This means the jury's verdict in favor of Moderna on the infringement issue stands.

Q: What is the role of a jury in patent infringement cases?

In this case, a jury had previously made findings. However, the district court granted summary judgment of non-infringement, and the appeal focused on that legal determination. The appellate court reviewed the summary judgment decision.

Q: What is the role of the district court in patent cases?

The district court is the trial court where patent cases are initially heard. It handles pre-trial matters, claim construction (often through a Markman hearing), potential jury trials, and issues judgments, including summary judgments of non-infringement.